Meta facebook tracking pixel

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses a person’s own T-cells (a type of white blood cell) to treat certain blood cancers.

Our immune system is a complex network of organs, cells and molecules that protects us from foreign substances that can cause infection, such as bacteria, fungi and viruses. In addition to finding and destroying foreign substances, the immune system can also locate and attack abnormal cells. There are two main parts of the immune system:

  • Innate immunity, a defense system we are born with, is the ability of the body to immediately protect itself against cancer, foreign organisms and toxins.
  • Adaptive immunity is a learned defense system that develops in response to exposure to a specific foreign substance. The adaptive immune system works in one of two ways:
  • Cell-mediated, in which T-cells identify and destroy abnormal cells, including cancer cells.
  • Humoral, also called antibody-mediated, in which B-cells (a type of white blood cell called a lymphocyte) make antibodies (specific blood proteins) that identify and destroy foreign substances.

The purpose of cancer-targeting immunotherapy is to modify the immune system to recognize that the cancer is foreign to the body and needs to be attacked. This can be difficult, because the differences between cancer cells and healthy cells are often quite small and hard to detect.

In addition to CAR T-cell therapy, immunotherapy approaches fall into the following main categories:

  • Checkpoint inhibitors are designed to block “immune checkpoint” molecules that shield cancer cells. These drugs are designed to remove the shield so that the immune system can attack cancer cells.

  • Monoclonal antibodies are lab-generated proteins that target specific tumor antigens (substances that the immune system sees as being foreign or dangerous). Some monoclonal antibodies help the immune system recognize and destroy cancer cells.

  • Bispecific antibodies are lab-generated proteins that target specific tumor antigens (as do monoclonal antibodies) but also bind proteins on the surface of T-cells. This allows the T-cells to get close to and destroy the cancer cells.

  • Therapeutic vaccines can boost the immune system and have the potential to treat cancer or prevent it from recurring (coming back) after treatment. The U.S. Food and Drug Administration (FDA) has approved vaccines for certain cancers. Additionally, a number of types of vaccines are being studied in clinical trials.

CAR T-Cell Therapy

CAR T-cell therapy is currently approved by the FDA for certain types of relapsed (recurred) or refractory (not responding to treatment) lymphomas:

  • Diffuse large B-cell lymphoma
  • Primary mediastinal B-cell lymphoma
  • High grade B-cell lymphoma
  • Transformed follicular lymphoma
  • Mantle cell lymphoma

It is also approved for the treatment of acute lymphoblastic leukemia in patients up to age 25 and, as of March 2021, for the treatment of relapsed or refractory multiple myeloma.

Based on a person’s individual circumstances, CAR T-cell therapy may be conducted on an outpatient basis or require a hospital admission. The process is similar regardless of the drug used or the specific type of cancer:

  • Blood is drawn from the patient via an intravenous catheter (a flexible tube).
  • T-cells are isolated from the rest of the blood.
  • In a laboratory, the T-cells are genetically re-engineered by adding a chimeric antigen receptor to their surface.
  • The modified T-cells (which are now CAR T-cells) are expanded to number in the hundreds of millions.
  • The CAR T-cells are infused back into the patient where they target and destroy cancer cells.

The following chimeric antigen receptors are approved by the FDA:

  • Axicabtagene ciloleucel (Yescarta) for the treatment of certain types of B-cell lymphoma.
  • Tisagenlecleucel (Kymriah) for the treatment of certain types of B-cell lymphoma and for the treatment of acute lymphoblastic leukemia in patients up to age 25.
  • Brexucabtagene autoleucel (Tecartus) for the treatment of mantle cell lymphoma.
  • Lisocabtagene maraleucel (Breyanzi) for the treatment of large B-cell lymphoma.
  • Idecabtagene vicleucel (Abecma) for the treatment of multiple myeloma after four or more prior lines of therapy.
  • Ciltacabtagene autoleucel (Carvykti), also for the treatment of multiple myeloma after four or more prior lines of therapy.

Immunotherapy, including CAR T-cell therapy, travels through the bloodstream to help prompt what is called an “immune response.” Because immunotherapy can affect healthy cells as well as cancer cells, certain side effects may be experienced, including digestive tract symptoms, loss of appetite, fatigue and flu-like symptoms. (See the “General Side Effects” section of this booklet for tips on managing these potential side effects.)

Report any side effects that you experience to your health care team right away so they can help you manage them. The side effects can range in severity; reporting them early can minimize their intensity and seriousness. It’s important to remember that not all people experience all side effects, and people may experience side effects not listed here.

CAR T-cell therapy has its own specific potential side effects, including:

  • Cytokine-Release Syndrome (CRS). The infusion of CAR T-cells into the body results in the production of large numbers of cytokines (molecules that help cells communicate), which can cause the immune system to become excessively active. This can lead to CRS, with symptoms such as high fever and flu-like symptoms. These side effects can be controlled and reversed with cytokine-blocking drugs and steroids.
  • B-Cell Aplasia. The FDA-approved CAR T-cell therapy products destroy normal as well as cancerous B-cells, which can cause B-cell aplasia (low numbers of B-cells), in which the body is less able to make the antibodies that protect against infection. Immunoglobulin replacement, administered intravenously, can be used to treat or prevent infection.
  • Tumor Lysis Syndrome (TLS). When cancer cells break down (are destroyed) very quickly, they release large amounts of potassium, phosphate and uric acid into the blood. This can result in TLS, a group of conditions that can cause neurological, heart or kidney problems. TLS is managed by medicines that decrease potassium and uric acid levels in the blood. Medicines may also be prescribed that help increase urination.
  • Changes in Cognition. Some changes in cognition (thought processes) ranging from mild to severe can occur within several days of CAR T-cell therapy. The symptoms are often treated with steroids and are almost always reversible.

Because of these possible side effects, people who have undergone CAR T-cell therapy should stay close to their treatment location for at least four weeks, so they can be closely monitored by their healthcare team.

Side Effects of Chemotherapy

People being treated with CAR T-cell therapy receive a low dose of chemotherapy, which gives the CAR T-cells a better chance to fight the cancer. Because of this, certain side effects may be experienced, including:

  • Hair loss
  • Increased risk of infection (from having too few white blood cells)
  • Easy bruising or bleeding
  • Changes in memory or thinking
  • Peripheral neuropathy (numbness or tingling in hands and feet)

Managing Digestive Tract Symptoms

Nausea and vomiting

  • Avoid food with strong odors, as well as overly sweet, greasy, fried or highly seasoned food.
  • Eat meals that are chilled, which often makes food more easily tolerated.
  • Nibble on dry crackers or toast. These bland foods are easy on the stomach.
  • Having something in your stomach when you take medication may help ease nausea.


  • As hydration is important to avoid constipation, make sure to drink plenty of fluids. Also, limit your intake of caffeine and alcoholic beverages, as they can cause dehydration.
  • Include foods high in fiber in your daily diet, such as fruit (especially pears and prunes), vegetables and cereals. If your health care team approves, you may want to add synthetic fiber to your diet, such as Metamucil, Citrucel or FiberCon.
  • Be as physically active as you can, after checking with your health care team on the level of physical activity that is right for you.
  • If your doctor has prescribed a “bowel regimen,” make sure to follow it exactly.


  • Drink plenty of water. Ask your doctor about using drinks such as Gatorade which provide electrolytes. Electrolytes are body salts that must stay in balance for cells to work properly.
  • Over-the-counter medicines such as loperamide (Imodium A-D and others) and prescription drugs are available for diarrhea but should be used only if necessary. If the diarrhea is bad enough that you need medicine, discuss it with your doctor or nurse.
  • Choose fiber-dense foods such as whole grains, fruits and vegetables, all of which help form stools.
  • Avoid food high in refined sugar and those sweetened with sugar alcohols such as sorbitol and mannitol.

Managing Loss of Appetite

  • Eating small meals throughout the day is an easy way to take in more protein and calories, which will help maintain your weight. Try to include protein in every meal.
  • To keep from feeling full early, avoid liquids with meals or take only small sips (unless you need liquids to help swallow). Drink most of your liquids between meals.
  • Keep high-calorie, high-protein snacks on hand such as hard-boiled eggs, peanut butter, cheese, ice cream, granola bars, liquid nutritional supplements, puddings, nuts, canned tuna or trail mix.
  • If you are struggling to maintain your appetite, talk to your health care team about whether appetite-building medication could be right for you.

Managing Fatigue

Fatigue (extreme tiredness not helped by sleep) is one of the most common side effects of many cancer treatments. Here are a few tips that may help reduce fatigue:

  • Take several short naps or breaks during the day.
  • Take short walks or do some light exercise, if possible.
  • Try easier or shorter versions of the activities you enjoy.
  • Ask your family or friends to help you with tasks you find difficult or tiring.
  • Save your energy for things you find most important.

There are also prescription medications that may help. Your health care team can provide guidance on whether medication is the right approach for your individual circumstances.

Fatigue can be a symptom of other illnesses, such as anemia, diabetes, thyroid problems, heart disease, rheumatoid arthritis or depression. Be sure to ask your doctor if they think any of these conditions may be contributing to your fatigue.

It can also be beneficial to speak with an oncology social worker or oncology nurse to help manage your fatigue. These professionals can work with you to manage any emotional or practical concerns that may be causing symptoms and help you find ways to cope.

Managing Flu-Like Symptoms

The fever and aches that may occur with immunotherapy treatments can be managed with a combination of rest and medication. Acetaminophen (such as Tylenol) is often a doctor’s first choice to treat these symptoms. Nonsteroidal anti-inflammatory drugs (NSAIDs) can also help, but should be taken only if recommended by your doctor, as they can cause other side effects. NSAIDs include aspirin, ibuprofen (Motrin and others) and naproxen (Naprelan, Midol, Aleve and others).

Q: What questions should I ask my oncologist about CAR T-cell therapy as a possible treatment approach?

A: Specific questions to discuss with your oncologist include:

  • Does CAR T-cell therapy have a role in treating my type of cancer, alone or in combination with other treatments?
  • Is there an FDA-approved CAR T-cell therapy for my type of cancer?
  • Is there anything I need to do to prepare for CAR T-cell therapy?
  • Will I have to stay in the hospital for any period of time?
  • Will receiving CAR T-cell therapy have an effect on future treatment decisions?
  • What side effects am I most likely to experience?
  • How will the effectiveness of the CAR T-cell therapy be monitored?

Q: What research is currently being conducted on CAR T-cell therapy?

A: There are a number of areas of CAR T-cell therapy research, including:

  • Using CAR T-cell therapy as a treatment approach for other types of cancer.
  • Collecting T-cells from donors, which eliminates one step in the process for the patient.
  • Creating CAR T-cells inside the body.
  • Developing CAR T-cells that have “off switches” to help limit side effects.
  • Using gene-editing technology to more precisely engineer the T-cells.
  • Combining chimeric antigen receptors with other immunotherapies.

Q: What is a treatment summary and why is important?

A: Keeping your own records up-to-date in the form of a treatment summary can be helpful, as it allows you and your family members to have instant access to the specifics of your cancer diagnosis and treatment. A treatment summary should include:

  • Your name and date of birth.
  • Date of diagnosis.
  • Prescribed therapy/therapies, including dates started and stopped and dosages when appropriate.
  • Dates and types of baseline and post-diagnosis testing and the results of these tests.
  • Other medications and supplements you are taking.
  • Names, affiliations and contact information of all members of your health care team.

Ask the members of your health care team what they suggest be included. Take your personal record with you when you visit any doctor, not just your oncologist.

Browse by Diagnosis

Browse by Topic

Thumbnail of the PDF version of Understanding the Role of CAR T-Cell Therapy in Treating Cancer

Download a PDF(410 KB) of this publication.

This e-booklet is supported by Bristol Myers Squibb and Novartis Oncology.

Last updated Thursday, April 6, 2023

The information presented in this publication is provided for your general information only. It is not intended as medical advice and should not be relied upon as a substitute for consultations with qualified health professionals who are aware of your specific situation. We encourage you to take information and questions back to your individual health care provider as a way of creating a dialogue and partnership about your cancer and your treatment.

Back to Top

Terms of Use and Privacy Policy

By using our website, you agree to our recently updated Privacy Policy . Here you can read more about our use of cookies which help us make continuous improvements to our website. Privacy Policy.